secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aurinia Pharmaceuticals Inc. (AUPH)
CIK:        0001600620
Form:       8-K/A
Filed at:   2022-01-07T23:59:59+00:00
Accession:  0001628280-22-000527
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aurinia reports positive 3-year AURORA 2 data for LUPKYNIS; no new safety signals
--------------------------------------------------------------------------------

- eGFR stable over 36 months; +2.7 mL/min vs control from baseline.
- Serious AE rates: 19% voclosporin vs 24% control; 0 deaths in voclosporin arm vs 4 in placebo.
- Mean UPCR lower in voclosporin group at all time points over 3 years.
- Withdrawal rate: 12.9% voclosporin vs 15.0% control; drug well tolerated.
- AURORA 2 enrolled 216 LN patients; 90 voclosporin and 78 control completed 36 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1600620/000162828022000527/0001628280-22-000527-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1600620/000162828022000527/auph-20211209.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-000527

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer